Name | Number of supported studies | Average coverage | |
---|---|---|---|
ciliated cell | 15 studies | 30% ± 12% | |
endothelial cell | 15 studies | 27% ± 12% | |
fibroblast | 10 studies | 30% ± 14% | |
myofibroblast cell | 9 studies | 26% ± 10% | |
mast cell | 7 studies | 23% ± 11% | |
epithelial cell | 6 studies | 26% ± 7% | |
adventitial cell | 5 studies | 23% ± 4% | |
erythrocyte | 5 studies | 33% ± 12% | |
vein endothelial cell | 4 studies | 33% ± 19% | |
mesothelial cell | 4 studies | 35% ± 13% | |
secretory cell | 4 studies | 26% ± 9% | |
duct epithelial cell | 3 studies | 20% ± 2% | |
capillary endothelial cell | 3 studies | 43% ± 27% | |
erythroblast | 3 studies | 45% ± 14% | |
endothelial cell of vascular tree | 3 studies | 21% ± 4% | |
enteroendocrine cell | 3 studies | 25% ± 1% | |
goblet cell | 3 studies | 28% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
thymus | 100% | 708.01 | 653 / 653 | 99% | 30.38 | 599 / 605 |
breast | 100% | 981.50 | 459 / 459 | 99% | 44.16 | 1106 / 1118 |
ovary | 100% | 1929.41 | 180 / 180 | 99% | 43.52 | 424 / 430 |
prostate | 100% | 1909.76 | 245 / 245 | 98% | 50.90 | 491 / 502 |
kidney | 100% | 747.21 | 89 / 89 | 98% | 43.18 | 880 / 901 |
lung | 100% | 1315.34 | 577 / 578 | 97% | 39.56 | 1124 / 1155 |
stomach | 99% | 423.28 | 357 / 359 | 97% | 33.28 | 276 / 286 |
pancreas | 95% | 335.36 | 313 / 328 | 99% | 69.03 | 176 / 178 |
intestine | 99% | 834.33 | 953 / 966 | 95% | 35.81 | 502 / 527 |
bladder | 100% | 1326.81 | 21 / 21 | 92% | 42.23 | 463 / 504 |
adrenal gland | 100% | 2174.55 | 258 / 258 | 89% | 50.44 | 205 / 230 |
esophagus | 98% | 411.14 | 1416 / 1445 | 86% | 23.11 | 157 / 183 |
uterus | 99% | 652.86 | 169 / 170 | 83% | 37.53 | 383 / 459 |
skin | 95% | 355.77 | 1721 / 1809 | 84% | 28.04 | 396 / 472 |
lymph node | 0% | 0 | 0 / 0 | 100% | 25.29 | 29 / 29 |
adipose | 100% | 1640.70 | 1201 / 1204 | 0% | 0 | 0 / 0 |
spleen | 100% | 490.41 | 240 / 241 | 0% | 0 | 0 / 0 |
blood vessel | 93% | 543.56 | 1236 / 1335 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 82% | 33.55 | 37 / 45 |
brain | 38% | 97.79 | 1005 / 2642 | 40% | 7.65 | 284 / 705 |
heart | 76% | 479.06 | 658 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 74% | 12.47 | 59 / 80 |
peripheral blood | 57% | 240.91 | 531 / 929 | 0% | 0 | 0 / 0 |
liver | 19% | 61.69 | 44 / 226 | 31% | 7.30 | 125 / 406 |
muscle | 14% | 26.80 | 111 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0006954 | Biological process | inflammatory response |
GO_0050965 | Biological process | detection of temperature stimulus involved in sensory perception of pain |
GO_0005615 | Cellular component | extracellular space |
GO_0005737 | Cellular component | cytoplasm |
GO_0008201 | Molecular function | heparin binding |
GO_0005515 | Molecular function | protein binding |
GO_0008191 | Molecular function | metalloendopeptidase inhibitor activity |
Gene name | LXN |
Protein name | Latexin Latexin (Endogenous carboxypeptidase inhibitor) (ECI) (Protein MUM) (Tissue carboxypeptidase inhibitor) (TCI) |
Synonyms | |
Description | FUNCTION: Hardly reversible, non-competitive, and potent inhibitor of CPA1, CPA2 and CPA4. May play a role in inflammation. . |
Accessions | Q9BS40 ENST00000264265.4 ENST00000482640.5 H7C5A4 |